3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism of Vein VTE in Colorectal Cancer
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Kidney Neoplasms
1
Fatigue
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Dalteparin
4
Saline Solution
3
Gemcitabine
3
Enoxaparin
3
Warfarin
2
Tinzaparin
2
Heparin, Low-Molecular-Weight
2
Fondaparinux
2
Aspirin
2
130-nm albumin-bound paclitaxel
2
palbociclib
1
isoquercitrin
1
enoxaparin sodium
1
edoxaban
1
apixaban
1
alvocidib
1
Tranexamic Acid
1
Sodium Chloride
1
Sodium Bicarbonate
1
Rivaroxaban
1
Pentetic Acid
1
PEGPH20
1
Nadroparin
1
Minocycline
1
Ketoconazole
1
Heparin
1
Fluorodeoxyglucose F18
1
Fluoridation
1
Estramustine
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thromboembolism
×
isoquercitrin
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled